Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Show more
Location: 110 Allen Road, Basking Ridge, NJ, 07920, United States | Website: https://www.lisata.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
23.3M
52 Wk Range
$1.87 - $4.20
Previous Close
$2.74
Open
$2.60
Volume
10,198
Day Range
$2.55 - $2.75
Enterprise Value
-1.068M
Cash
25.83M
Avg Qtr Burn
-4.433M
Insider Ownership
20.18%
Institutional Own.
9.11%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LSTA12 (HONEDRA®) Details Critical limb ischemia | Phase 3 Update | |
Certepetide (LSTA1) Details Pancreatic cancer | Phase 2b Data readout | |
LSTA1 + temozolomide Details Cancer, Glioblastoma, Glioma | Phase 2a Data readout | |
LSTA1 + Standard of care Details Cholangiocarcinoma | Phase 2a Data readout | |
LSTA1 + Durvalumab/gemcitabine/nab-paclitaxel Details Pancreatic cancer, Cancer | Phase 1/2 Data readout | |
LSTA1 + gemcitabine/nab-paclitaxel Details Pancreatic cancer | Phase 1/2 Data readout | |
LSTA1 + FOLFIRINOX (neoadjuvant) + panitumumab Details Pancreatic cancer, Colorectal cancer | Phase 1/2 Data readout | |
LSTA1 + nivolumab/FOLFIRINOX, Details Cancer, Gastroesophageal adenocarcinomas | Phase 1/2 Update | |
Gemcitabine/nab-paclitaxel + continuous infusion of certepetide/placebo Details Pancreatic cancer, Cancer | Phase 1/2 Initiation | |
OLOGO (CLBS14) Details Angina | Failed Discontinued | |
XOWNA (CLBS16) Details Coronary Microvascular Dysfunction | Failed Discontinued | |
LSTA201 (CLBS201) Details Chronic kidney disease | Failed Discontinued |